Advances in Rational Combination Chemotherapy

References

• DeVita V T, Jr. The relationship between tumor mass and resistance to chemotherapy. Cancer 1983; 51: 1209–1220
   PubMed Web of Science ®Google Scholar
• Frei E. The national cancer chemotherapy program. Science 1982; 217: 600–606
   PubMed Web of Science ®Google Scholar
• Cadman E C. The design of rational combination chemotherapy for cancer. West J Med 1984; 140: 921–928
   PubMedGoogle Scholar
• Seidman H, Mushinok M H, Gelb S K, Silverberg E. Probabilities of eventually developing or dying of cancer—United Stales. 1985, CA 1985; 35: 36–56
   Google Scholar
• Silverberg E. Cancer statistics. 1985, CA 1985; 35: 19–35
   Google Scholar
• DeVita V T, Schein P S. The use of drugs in combination for the treatment of cancer. N Engl J Med 1973; 288: 998–1006
   PubMed Web of Science ®Google Scholar
• Goldie J H, Coldman A J, Gudanskas G A. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 1982; 66: 439–449
   PubMedGoogle Scholar
• Goldstein D P. The chemotherapy to gestational trophoblastic disease. Principles of clinical management. JAMA 1972; 220: 209–213
   PubMed Web of Science ®Google Scholar
• Li M C. Trophoblastic disease: National history, diagnosis and treatment. Ann Intern Med 1970; 74: 102–112
   Web of Science ®Google Scholar
• Li M C, Whitmore W F, Jr., Golby R, et al. Effects of combined drug therapy on metastatic cancer of the testis. JAMA 1960; 174: 1291–1299
   PubMed Web of Science ®Google Scholar
• Mackenzie A R. Chemotherapy of metastatic testis cancer: Results in 154 patients. Cancer 1966; 19: 1369–1376
   PubMed Web of Science ®Google Scholar
• Goodman L S, Wintrobe M W, Dameshek W, et al. Nitrogen mustard therapy. JAMA 1946; 132: 126–132
   PubMed Web of Science ®Google Scholar
• Jackson H, Jr, Parker F, Jr. Hodgkins Disease and Allied Disorders. Oxford University Press, New York 1947
   Google Scholar
• Farber S, Diamond L K, Mercer R D, et al. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). N Engl J Med 1954; 238: 787–793
   Google Scholar
• DeVita V T, Jr. The relationship between tumor mass and resistance to chemotherapy. Implications for surgical adjuvant treatment of cancer. Cancer 1983; 51: 1209–1220
   PubMed Web of Science ®Google Scholar
• Li M C, Hertz R, Spencer D B. Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma. Proc Soc Exp Biol Med 1956; 93: 361–366
   PubMed Web of Science ®Google Scholar
• Goldin A, Mantel N. The employment of combinations of drugs in the chemotherapy of neoplasia: A review. Cancer Res 1957; 17: 635–654
   PubMed Web of Science ®Google Scholar
• Luhrs W. Experiments on the combined chemotherapeutic influence on inoperable, x-ray unsuitable patients suffering from bronchial carcinoma: Clinical studies with combinations of TEM and antimetabolites. Acta Unio Int Contr Cancrum 1957; 13: 424–427
   PubMedGoogle Scholar
• Skipper H E, Schobel F M, Jr, Wilcox W S. Experimental evaluation of potential anticancer agents. XII. On the criteria and kinetics associated with “curability” of experimental leukemia. Cancer Chemother Rep 1964; 35: 1–111
   PubMedGoogle Scholar
• Skipper H E, Schobel F M, Jr., Wilcox W S. Experimental evaluation of potential anticancer agents. XIV. Further study of certain basic concepts underlying chemotherapy of leukemia. Cancer Chemother Rep 1965; 45: 5–28
   PubMedGoogle Scholar
• Skipper H E, Thomson J R, Bell M. Attempts at dual blocking of biochemical events in cancer chemotherapy. Cancer Res 1954; 14: 503–507
   PubMed Web of Science ®Google Scholar
• Potter V R. Sequential blocking of metabolic pathways in vivo. Proc Soc Exp Biol Med 1951; 76: 41–46
   PubMed Web of Science ®Google Scholar
• Casciato D A, Lowitz B B. Principles of radiotherapy and chemotherapy. Manual of Bedside Oncology, D A Casciato, B B Lowitz. Little, Brown and Co., Boston 1983; 9–29
   Google Scholar
• Bonadonna G. Chemotherapy strategies to improve the control of Hodgkins disease: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1982; 42: 4309–4320
   PubMed Web of Science ®Google Scholar
• Nissen N I, Pajak T, Glidewell O, et al. Overview of four clinical studies of chemotherapy for stage III and IV non-Hodgkin's lymphomas by the cancer and leukemia group B. Cancer Treat Rep 1975; 61: 248–250
   Google Scholar
• DeVita V T, Jr, Canellos G P, Chabner B, et al. Advanced diffuse histiocytic lymphoma, a potentially curable disease. Results with combination chemotherapy. Lancet 1975; 1: 248–250
   PubMed Web of Science ®Google Scholar
• McKelvey E M, Gottleib J A, Wilson H E, et al. Hydroxyl-daunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976; 38: 1484–1493
   PubMed Web of Science ®Google Scholar
• Schein P S, DeVita V T, Hubbard S, et al. Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Ann Intern Med 1976; 85: 417–422
   PubMed Web of Science ®Google Scholar
• Sweet D L, Golomb H M, Ultman J E, et al. Cyclophosphamide. vincristine, methotrexate with leucovorin rescue, and cytarabine (COMLA) combination sequential chemotherapy for advanced diffuse histocytic lymphoma. Ann Intern Med 1980; 92: 785–790
   PubMed Web of Science ®Google Scholar
• Fisher R I, DeVita V T, Hubbard S M, et al. ProMACE-MOPP combination chemotherapy: Treatment of diffuse lymphomas (abstract). Proc Am Soc Clin Oncol 1980; 21: 468
   Google Scholar
• Laurence J, Coleman M, Allen S L, et al. Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen. Ann Intern Med 1982; 97: 190–195
   PubMed Web of Science ®Google Scholar
• Anderson T, Waldmann T A, Javad-Pour N, Glatstein E. Testicular germ-cell neoplasma: Recent advances in diagnosis and therapy. Ann Intern Med 1979; 90: 373–385
   PubMed Web of Science ®Google Scholar
• Richardson G S, Scully R E, Nikrui N, Nelson J H. Common epithelial cancer of the ovary. N Engl J Med 1985; 312: 415–424; 474–483
   PubMed Web of Science ®Google Scholar
• Gale R P, Foon K A, Cline M J, et al. Intensive chemotherapy for acute myelogenous leukemia. Ann Intern Med 1981; 94: 753–757
   PubMed Web of Science ®Google Scholar
• Foon K A, Gale R P. Controversies in the therapy of acute myelogenous leukemia. Am J Med 1982; 72: 963–979
   PubMed Web of Science ®Google Scholar
• Zeigler J L, Deisseroth A B, Applebaum F R, et al. Burkitt's lymphoma—a model for intensive chemotherapy. Semin Oncol 1977; 4: 317–323
   PubMed Web of Science ®Google Scholar
• Mauer A M. Therapy of acute lymphoblastic leukemia in childhood. Blood 1980; 56: 1–9
   PubMed Web of Science ®Google Scholar
• Schwartz A D. Neuroblastoma and Wilms' tumor. Med Clin North Am 1977; 61: 1053–1071
   PubMed Web of Science ®Google Scholar
• Rosen G, Cafarros B, Mesende C, et al. Curability of Ewing's sarcoma and considerations for future therapeutic trials. Cancer 1978; 41: 888–899
   PubMed Web of Science ®Google Scholar
• Howarth C, Meyer D, Hustu O, et al. Stage-related combined modality treatment of retinoblastoma. Cancer 1980; 45: 851–858
   PubMed Web of Science ®Google Scholar
• Rivard G, Ortgega J, Hittle R, et al. Intensive chemotherapy as primary treatment for rhabdomyosarcoma of the pelvis. Cancer 1975; 36: 1593–1597
   PubMed Web of Science ®Google Scholar
• George R P, Poth J L, Gordon D, Schrier S. Multiple myeloma-intermittent combination chemotherapy compared to continuous therapy. Cancer 1972; 29: 1665–1670
   PubMed Web of Science ®Google Scholar
• Alberts D S, Durie B G, Salmon S E. Doxorubicin/B.C.N.U. chemotherapy for multiple myeloma in relapse. Lancet 1976; 1: 926–928
   PubMed Web of Science ®Google Scholar
• Alexanian R, Dreicer R. Chemotherapy for multiple myeloma. Cancer 1984; 53: 583–588
   PubMed Web of Science ®Google Scholar
• Case D C, Jr, Lee B J, III, Clarkson B D. Improved survival times in multiple myeloma treated with melphalan. prednisone. cyclophosphamide, vincristine and BCNU:M-2 protocol. Am J Med 1977; 63: 897–903
   PubMed Web of Science ®Google Scholar
• Aisner J, Whitacre M, Van Echo D A, Wiernick P H. Combination chemotherapy for small cell carcinoma of the lung: Continuous versus alternating non-cross-resistant combinations. Cancer Treat Rep 1982; 66: 221–230
   PubMedGoogle Scholar
• Sarna G P, Lowitz B B, Haskell C M, et al. Chemoimmunotherapy for unresectable bronchogenic carcinoma. Cancer Treat Rep 1978; 62: 681–687
   PubMedGoogle Scholar
• Cohen M H, Creaven P J, Fassieck B E, et al. Intensive chemotherapy of small cell bronchogeni carcinoma. Cancer Treat Rep 1977; 61: 349–354
   PubMedGoogle Scholar
• Carter S K. Integration of chemotherapy into combined modality treatment of solid tumors VII. Adenocarcinoma of the breast. Cancer Treat Rev 1976; 3: 141–174
   PubMed Web of Science ®Google Scholar
• Jones S E, Durie B G, Salman S E. Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer. Cancer 1975; 36: 90–97
   PubMed Web of Science ®Google Scholar
• MacDonald J S, Schein P S, Woolley P V, et al. 5-fluorouracil, Mitomycin C. and Adriamycin (FAM): A new combination chemotherapy program for advanced gastric carcinoma. Ann Intern Med 1980; 93: 533–536
   PubMed Web of Science ®Google Scholar
• Douglass H, Lavin P T, Goudsmit A, Klaassen D J. Phase l-II evaluation of combinations of methyl-CCNU, mitomycin C. adriamycin and 5-fluorouracil in advanced measurable gastric cancer (Est-2277). Proc Am Soc Clin Oncol 1983; 2: 121
   Google Scholar
• Becker D, Schumacher D P. O.p'DDD therapy in invasive adrenocortical carcinoma. Ann Intern Med 1975; 82: 677–679
   PubMed Web of Science ®Google Scholar
• Moertel C G, Hanley J A, Johnson L A. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 1980; 303: 1189–1194
   PubMed Web of Science ®Google Scholar
• Jaffe N, Frei E, III, Watts M, Traggis D. High dose methotrexate in osteogenic sarcoma: a 5-year experience. Cancer Treat Rep 1978; 62: 259–264
   PubMedGoogle Scholar
• Rosen G, Marcove R C, Caparros B, et al. Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery. Cancer 1979; 43: 2163–2177
   PubMed Web of Science ®Google Scholar
• Gasparini M, Bellan F F, Musumeci R, et al. Response and survival of patients with metastatic neuroblastoma after combination chemotherapy with adriamycin (NSC-123127), cyclophosphamide (NSC-25271), and vincristine (NSC 67574). Cancer Chemother Rep 1974; 58: 365–370
   PubMedGoogle Scholar
• Leikin A, Evans A, Heyn R, et al. The impact of chemotherapy on advanced neuroblastoma. Survival of patients diagnosed in 1956, 1962, and 1966–68 in children's cancer study group A. J Pediatr 1974; 84: 131–134
   PubMed Web of Science ®Google Scholar
• Ureles A L. Diagnosis and treatment of malignant carcinoid syndrome. JAMA 1974; 229: 1346–1348
   PubMed Web of Science ®Google Scholar
• Moertel C G. Clinical management of advanced gastrointestinal cancer. Cancer 1975; 36: 675–682
   PubMed Web of Science ®Google Scholar
• Goldman J M. Modern approaches to the management of chronic granulocytic leukemia. Sem Hematol 1978; 15: 420–430
   PubMed Web of Science ®Google Scholar
• Sawitsky A, Rai K R, Glidewell O, et al. Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. Blood 1977; 50: 1049–1059
   PubMed Web of Science ®Google Scholar
• Oken M M, Kaplan M E. Combination chemotherapy with cyclophosphamide, vincristine, and prednisone in the treatment of refractory chronic lymphocytic leukemia. Cancer Treat Rep 1979; 63: 441–447
   PubMedGoogle Scholar
• White R D, Babayan R K, Krikorian J, et al. Adjuvant chemotherapy for stage Dl adenocarcinoma of the prostate. Urology 1983; 21: 270–272
   PubMed Web of Science ®Google Scholar
• Merrin C E, Beckley S. Treatment of estrogen-resistant stage D carcinoma of the prostate with cis-diammine dichloro platinum. Presented at American Urological Association, 73rd Annual Meeting, Washington, DC, May, 1978
   Google Scholar
• Yap B S, Baker L H, Sinkovics J G, et al. Cyclophosphamide, vincristine, adriamycin, and DTIC (CY VADIC) combination chemotherapy for the treatment of advanced sarcomas. Cancer Treat Rep 1980; 64: 93–98
   PubMedGoogle Scholar
• Walker M D, Green S B, Byar D P, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980; 303: 1323–1329
   PubMed Web of Science ®Google Scholar
• Bitran J D, Desser R K, DeMeester T R, et al. Cyclophosphamide. adriamycin, methotrexate, and procarbazine (CAMP)—effective four-drug combination chemotherapy for metastatic non-oat cell. Cancer Treat Rep 1976; 60: 1225–1230
   PubMedGoogle Scholar
• Straus M J. Combination chemotherapy in advanced lung cancer with increased survival. Cancer 1976; 38: 2232–2241
   PubMed Web of Science ®Google Scholar
• Lindgren D, Cadman E, Erichson R, et al. Use of cisplatin, cyclophosphamide, vincristine, and doxorubicin for the treatment of non-small cell lung cancer. Cancer Treat Rep, 68: 1159–1161
   PubMedGoogle Scholar
• Maurer H M, Moon T, Donaldson M, et al. The intergroup rhabdomyosarcoma study. A preliminary report. Cancer 1977; 40: 2015–2026
   PubMed Web of Science ®Google Scholar
• Gottlieb L C, Hill C S, Jr. Chemotherapy of thyroid cancer with adriamycin. N Engl J Med 1974; 290: 193–197
   PubMed Web of Science ®Google Scholar
• Wasserman T H, Cornis R L, Goldsmith M, et al. Tabular analysis of the clinical chemotherapy of solid tumors. Cancer Chemother Rep 1975; 6: 399–419
   Google Scholar
• Al-Sarral M, Go T S, Kithier K, Voitkevicius V K. Primary liver cancer. A review of the clinical features, blood groups, serum enzymes, therapy, and survival of 65 cases. Cancer 1974; 33: 574–582
   PubMed Web of Science ®Google Scholar
• Johnson P J, Thomas H, Williams R, et al. Induction of remission in hepatocellular carcinoma with doxorubicin. Lancet 1978; 1: 1006–1009
   PubMed Web of Science ®Google Scholar
• Yagoda A. Chemotherapy of metastatic bladder cancer. Cancer 1980; 45: 1879–1888
   PubMed Web of Science ®Google Scholar
• Veronesi U, Adamus J, Aubert C, et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 1982; 307: 913–916
   PubMed Web of Science ®Google Scholar
• Leishman L, Steiger Z, Seydel H G, et al. Preoperative chemotherapy and radiation therapy for patients with cancer of the esophagus: A potentially curative approach. J Clin Oncol 1984; 2: 75–79
   PubMed Web of Science ®Google Scholar
• Cancer Treatment, C M Haskel. WB Saunders Co., Philadelphia 1980
   Google Scholar
• Chabner B A. The role of drugs in cancer treatment. Pharmacologic Principles of Cancer Treatment, B A Chabner. WB Saunders Co., Philadelphia 1980; 3–14
   Google Scholar
• Tannock I F. Biology of tumor growth. Hosp Prac 1983; 18: 81–93
   PubMed Web of Science ®Google Scholar
• Chabner B A. The evolution of cancer chemotherapy. Hosp Prac 1985; 20: 115–127
   Web of Science ®Google Scholar
• Tannock J F. Cell kinetics and chemotherapy: A critical review. Cancer Treat Rep 1978; 62: 1117–1131
   PubMedGoogle Scholar
• West G W, Weichselbaum R, Little J B. Limited penetration of methotrexate in human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy. Cancer Res 1980; 40: 3665–3668
   PubMed Web of Science ®Google Scholar
• Goldie J H, Coldman A J, Gudauskas G A. Rationale for the use of alternating non-cross resistant chemotherapy. Cancer Treat Rep 1982; 66: 439–449
   PubMedGoogle Scholar
• Goldie J H, Coldman A J. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63: 1727–1731
   PubMedGoogle Scholar
• Ling V. Genetic basis of drug resistance in mammalian cells. Drug and Hormone Resistance in Neoplasia, N Bruchovsky, J H Goldie. CRC Press, Boca Raton, FL 1981; 1–19
   Google Scholar
• Bhalla K, Nayak R, Grant S. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-B-D-arabinofuranosylcytosine. Cancer Res 1984; 44: 5029–5037
   PubMed Web of Science ®Google Scholar
• Grindey G B, Moran R G, Werkheiser W C. Approaches to the rational combination of antimetabolites for cancer chemotherapy. Drug Design, Vol V, E J Ariens. Academic Press, New York 1975; 169–249
   Google Scholar
• Grant S, Cadman E C. Modulation of 1-B-D-arabinofuranosyl-cytosine metabolism and cytotoxicity in L1210 cells by fluoro-pyrimidine pretreatment. Cancer Res 1982; 42: 3550–3556
   PubMed Web of Science ®Google Scholar
• Hill B T. The relevance of certain concepts of cell cycle kinetics. Biochim Biophys Acta 1978; 516: 389–412
   PubMed Web of Science ®Google Scholar
• DeVita V T. Cell kinetics and the chemotherapy of cancer. Cancer Chemo Rep 1971; 2: 23–33
   Google Scholar
• Heimer R, Cadman E C. Effect of methotrexate on the DNA-directed cytotoxicity produced by equitoxic doses of 5-fluorouracil and 5-fluorodeoxyuridine in murine leukemia cells. Rational Basis for Chemotherapy, B A Chabner. Alan R Liss, Inc., New York 1983; 93–105
   Google Scholar
• VonHoff D D. In vitro methods to predict for patient response to chemotherapy. Adv Pharm Chemother 1980; 17: 133–156
   PubMedGoogle Scholar
• Weisenthal L M, Lippman M E. Clonogenic and nonclonogenic in vitro chemosensitivity assays. Cancer Treat Rep 1985; 69: 615–632
   PubMedGoogle Scholar
• Chu M Y, Fischer G A. The incorporation of 3H-cytosine arabinoside and its effect on murine leukemia cells (L5178Y). Biochem Pharm 1968; 17: 753–767
   PubMed Web of Science ®Google Scholar
• Park C H, Bevgsaget D E, McCulloch E A. Mouse myeloma tumor stem cells: A primary cell culture assay. J Natl Cancer Inst 1971; 46: 411–422
   PubMed Web of Science ®Google Scholar
• Ogawa M, Bergsaget D E, McCulloch E A. Chemotherapy of mouse myeloma: Quantitative cell culture predictive of response in vivo. Blood 1973; 41: 7–15
   PubMed Web of Science ®Google Scholar
• Roper P R, Drewinko B. Comparison of in vitro methods to determine drug-induced cell lethality. Cancer Res 1976; 36: 2182–2188
   PubMed Web of Science ®Google Scholar
• Wright J C, Cober J P, Gunport S L, et al. Further investigation of the relation between the clinical and tissue culture response to chemotherapeutic agents on human cancer. Cancer 1962; 15: 284–293
   PubMed Web of Science ®Google Scholar
• Salmon S E, Hamburger A W, Soehnlen B, et al. Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med 1978; 298: 1321–1327
   PubMed Web of Science ®Google Scholar
• Salmon S E. in vitro assay for sensitivity to anticancer drugs. Hosp Prac 1985; 20: 133–148
   Web of Science ®Google Scholar
• Marsoni S, Wittes R. Clinical development of anticancer agents—a rational cancer institute perspective. Cancer Treat Rep 1984; 68: 77–85
   PubMedGoogle Scholar
• Chu M Y, Fischer F A. The incorporation of 3H-cytosine arabinoside and its effect on murine leukemia cells (L5178Y). Biochem Pharm 1968; 17: 752–761
   Google Scholar
• Hamburger A W, Salmon S E. Primary bioassay of human tumor stem cells. Science 1977; 197: 461–463
   PubMed Web of Science ®Google Scholar
• Welander C E, Morgan T M, Homesley H D. Multiple factors predicting responses to combination chemotherapy in patients with ovarian cancers. Human Tumor Cloning, S E Salmon, J M Trend. Grune & Stratton, Orlando 1984; 521–534
   Google Scholar
• Cadman E C, Heimer R, David L. Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: Explanation for drug synergism. Science 1979; 205: 1135–1137
   PubMed Web of Science ®Google Scholar
• Cadman E C, Eiferman F. Mechanism of synergistic cell killing when methotrexate precedes cytosine arabinoside. Study of L1210 and human leukemic cells. J Clin Invest 1979; 64: 788–797
   PubMed Web of Science ®Google Scholar
• Cadman E C, Grant S, Benz C C. Biochemical modulation as a guide to rational combination chemotherapy for the treatment of cancer. Adrenal and Endocrine Tumors in Children, G B Humphrey, et al. Martinus Nijhoff Publishers, Boston 1983; 101–122
   Google Scholar
• Benz C, De Gregorio M, Saks S, et al. Sequential infusions of methotrexate and 5-fluorouracil in advanced cancer: Pharmacology, toxicity and response. Cancer Res 1985; 45: 3354–3358
   PubMed Web of Science ®Google Scholar
• Benz C, Schoenberg M, Choti M, Cadman E. Schedule-dependent cytotoxicity of methotrexate and 5-fluorouracil in human colon and breast tumor cell lines. J Clin Invest 1980; 66: 1162–1165
   PubMed Web of Science ®Google Scholar
• Jackson R C, Harkrader R J. Synergistic and antagonistic interactions of methotrexate and 1-β-D-arabinofuranosylcytosine in hepatoma cells. The modulating effect of purines. Biochem Pharm 1981; 30: 223–229
   PubMed Web of Science ®Google Scholar
• Bergerat J D, Green C, Drewinko B. Combination chemotherapy in vitro, IV. Response of human colon carcinoma cells to combinations using cis-diamminedichloroplatinum. Cancer Biochem Biophys 1979; 3: 173–180
   PubMedGoogle Scholar
• Sobrero A F, Bertino J R. Sequence-dependent synergism between dichloromethotrexate and cisplatin in a human colon carcinoma cell line. Cancer Treat Rep 1985; 69: 279–283
   PubMedGoogle Scholar
• Barchenal J H, Lockys L, Turkevich J, Gale G. Rationale of combination chemotherapy. Cisplatin, An Prestayko, S T Crookc, S K Carter. Academic Press, New York 1980; 113–124
   Google Scholar
• Drewinko B, Green C, Loo T L. Combination chemotherapy in vitro with cis-dichlorodiamminoplatinum (II). Cancer Treat Rep 1976; 60: 1619–1625
   PubMedGoogle Scholar
• Ritch P S, Occhipinti S J, Cunningham R E, Shackney S E. Schedule-dependent synergism of combinations of hydroxyurea with adriamycin and l-β-D-arabinofuranosyl cytosine with adriamycin. Cancer Res 1981; 41: 3881–3884
   PubMed Web of Science ®Google Scholar
• Bergerat J P, Drewinko B, Corry P, et al. Synergistic lethal effect of cis-dichlorodiamminoplatinum and 1-β-D-arabinofuranolsylcytosine. Cancer Res 1981; 41: 25–30
   PubMed Web of Science ®Google Scholar
• Rivera G, Avery T, Roberts D. Response of L1210 to combinations of cytosine arabinoside and VM-26 or VP16–213. Europ J Cancer 1975; 11: 639–647
   PubMed Web of Science ®Google Scholar
• Nelson J A, Parks R E. Biochemical mechanism for the synergism between 6-thioguanine and 6-(methylmercapto)purine ribonucleoside in sarcoma 180 cells. Cancer Res 1972; 32: 2034–2041
   PubMed Web of Science ®Google Scholar
• Sartorelli A C. Approaches to the combination chemotherapy of transplantable neoplasms. Progr Exp Tumor Res 1965; 6: 228–288
   PubMed Web of Science ®Google Scholar
• Paterson A FP, Warz M C. Mechanism of the growth inhibition potentiation arising from combination of 6-mercaptopurine with 6-(methylmercapto)purine ribonucleoside. Cancer Res 1970; 30: 2379–2381
   PubMed Web of Science ®Google Scholar
• Tarnowski G S, Stock C C. Effects of combinations of azaserine and of 6-diazo-5-oxo-L-norleucine with purine analogs and other antimetabolites in the growth of two mouse mammary carcinomas. Cancer Res 1957; 17: 1033–1039
   PubMed Web of Science ®Google Scholar
• Cadman E C, Benz C, Heimer R, O'Shaughnessy J. The effect of de novo purine synthesis inhibitors in 5-fluorouracil metabolism and cytotoxicity. Biochem Pharmacol 1981; 30: 2469–2478
   PubMed Web of Science ®Google Scholar
• Benz C, Cadman E, Gwin J, et al. Tamoxifen and 5-fluorouracil in breast cancer: Cytotoxic synergism in vitro. Cancer Res 1983; 43: 5298–5303
   PubMed Web of Science ®Google Scholar
• Benz C, Santos G, Cadman E. Tamoxifen and 5-fluorouracil in breast cancer: Modulation of cellular RNA. Cancer Res 1983; 43: 5304–5308
   PubMed Web of Science ®Google Scholar
• Grant S, Rauscher F, III, Jakubowski A, Cadman E. Effect of W-(Phosphonacetyl)-L-aspartate on 5-azacytidine metabolism in P388 and L1210 cells. Cancer Res 1981; 41: 410–418
   PubMed Web of Science ®Google Scholar
• Plagemann P GW, Marz R, Wohlheuter R M. Transport and metabolism of deoxycytidine and 1-β-d-arabinofuranosylatosine into culture Novikoff rat hepatoma cells, relationship to phosphorylation, and regulation of triphosphate synthesis. Cancer Res 1978; 38: 978–989
   PubMed Web of Science ®Google Scholar
• Cadman E C, Heimer R, Benz C. The influence of methotrexate pretreatment on 5-fluorouracil metabolism in L1210 cells. J Biol Chem 1981; 256: 1695–1704
   PubMed Web of Science ®Google Scholar
• Momparler R L, Vesely J, Momparler L F, Rivard G E. Synergistic action of 5-aza-2′-deoxycytidine and 3-deazauridine on L1210 leukemic cells and EMT6 tumor cells. Cancer Res 1979; 39: 3822–3827
   PubMed Web of Science ®Google Scholar
• Jackson R L. The regulation of thymidylate biosynthesis in Novikoff hepatoma cells and the effects of amethopterin. 5-fluorodeoxyuridine, and 3-deazauridine. J Biol Chem 1978; 253: 7440–7446
   PubMed Web of Science ®Google Scholar
• Cadman E C, Dix D E, Handschumacher R E. Clinical biological, and biochemical effects of purzofurin. Cancer Res 1978; 38: 682–688
   PubMed Web of Science ®Google Scholar
• Cadman E C, Eiferman F, Heimer R, Davis L. Pyrazofurin enhancement of 5-aza cytidine antitumor activity in L5178Y and human leukemia cells. Cancer Res 1978; 38: 4610–4617
   PubMed Web of Science ®Google Scholar
• Neil G L, Moxley T E, Mark R L. Enhancement by tetrahydrouridine of 1-βD—arabinofuranosylcytosine (cytarabine) oral activity in L1210 leukemic mice. Cancer Res 1970; 30: 2166–2172
   PubMed Web of Science ®Google Scholar
• Yalowich J C, Ross W E. Potentiation of etoposide-induced DNA damage by calcium antagonists in L1210 cells in vitro. Cancer Res 1984; 44: 3360–3365
   PubMed Web of Science ®Google Scholar
• Nelson J A, Drake S. Potentiation of methotrexate toxicity by dipyridamole. Cancer Res 1984; 44: 2493–2496
   PubMed Web of Science ®Google Scholar
• Cabral S. Effect of dipyridamole on methotrexate cytotoxicity and efflux in S-180 cells. Proc Natl Acad Sci 1984; 81: 3200–3203
   PubMed Web of Science ®Google Scholar
• Grem J L, Fischer P H. Augmentation of 5-fluorouracil cytotoxicity in human colon cancer cells by dipyridamole. Cancer Res 1985; 45: 2967–2972
   PubMed Web of Science ®Google Scholar
• Yang J L, Capizzi R, Contento M. Sequential dipyridamole retards Ara C efflux and results in synergistic cytotoxicity. Proc Am Assoc Cancer Res 1984; 25: 346
   Web of Science ®Google Scholar
• Lee T, Karon M, Momparler R L. Kinetic studies on phosphorylation of 5-azacytidine with the purified uridine-cytidine kinase from calf thymus. Cancer Res 1974; 34: 2482–2488
   PubMed Web of Science ®Google Scholar
• Lehninger A L. The biosynthesis of nucleotides. Biochemistry, A L Lenninger. Worth Publishers. Inc., New York 1976; 729–747
   Google Scholar
• Orengo A. Regulation of enzymatic activity by metabolites. 1. Uridine cytidine kinase of Novikoff ascites rat tumor. J Biol Chem 1969; 224: 2204–2209
   Google Scholar
• Grindey G B, Nichol C A. Interaction of drugs inhibiting different steps in the synthesis of DNA. Cancer Res 1972; 32: 527–531
   PubMed Web of Science ®Google Scholar
• Hoovis M L, Chu M Y. Enhancement of the antiproliferative action of 1-β-D-arabinofuranosyltosine by methotrexate in murine leukemic cells (L5178Y). Cancer Res 1973; 33: 521–525
   PubMed Web of Science ®Google Scholar
• Tattersall M HN, Harrap K R. Combination chemotherapy: The antagonism of methotrexate and cytosine arabinoside. Europ J Cancer 1973; 9: 229–232
   PubMed Web of Science ®Google Scholar
• Christenson S R, Damon L E, Cadman E C, Unpublished observations
   Google Scholar
• Iapalucci-Espinoza S, Franze-Fernandez M Z. Regulation of rRNA synthesis and processing in animal cells. Effect of nucleoside analogues. Biochem J 1982; 202: 325–332
   PubMed Web of Science ®Google Scholar
• Tsurus T, Lida H, Nojiri M, et al. Circumvention of vincristine and adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Res 1983; 43: 2905–2910
   PubMed Web of Science ®Google Scholar
• Gupta R S. Genetic, biochemical, and cross-resistance studies with mutants of Chinese hamster ovary cells resistant to the anticancer agents VM-26 and VP16–213. Cancer Res 1983; 43: 1568–1574
   PubMed Web of Science ®Google Scholar
• Ganapathi R, Gioborisk D, Schmidt H, et al. Calmodulin inhibitor trifluoperazine selectively enhances cytotoxic effects of strong vs. weak DNA binding antitumor drugs in doxorubicin-resistant P388 mouse leukemia cells. Biochem Biophys Res Commun 1985; 131: 912–919
   PubMed Web of Science ®Google Scholar
• Ganapathi R, Grabouski D, Schmidt H. Factors governing the modulation of vinca-alkaloid resistance in doxorubicin-resistant cells by the calmodulin inhibitor trifluoperazine. Biochem Pharm 1986; 35, (in press)
   PubMed Web of Science ®Google Scholar